Blog

Nagashree Seetharamu: Navigating Treatment Beyond 3 Years of Survival in Metastatic EGFR+ NSCLC

Photo from Nagashree Seetharamu/X

Apr 29, 2024, 05:46

Nagashree Seetharamu: Navigating Treatment Beyond 3 Years of Survival in Metastatic EGFR+ NSCLC

Nagashree Seetharamu, Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared a post on X/Twitter:

”Are people getting denials from insurance for treatment beyond 3 years of overall survival interval in metastatic setting (EFGR+ NSCLC) despite sending all the necessary documents?

Writing an appeal letter and trying to maintain professionalism.”

Source: Nagashree Seetharamu/X

cancer cancer metastasis cancer treatment Donald and Barbara Zucker School of Medicine EGFR lung cancer Lung cancer Nagashree Seetharamu Northwell Health School of Medicine NSCLC OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage